NeoCura IM
TM
The tumor microenvironment immuno-modulator NeoCura IM is composed of coding cytokine mRNAs that have an immunomodulatory activity. It is intended for immunotherapy of solid tumors. NeoCura IM can help patients use the specific immunoregulatory factors produced by their own cells to activate the body¡¯s innate and adaptive immune responses, enhance the body¡¯s antitumor ability, and thereby achieve the goal of killing the tumor or controlling malignant tumor progression. It can be used in combination with neoantigen therapy or other immunotherapies.
TM
TM
Product Highlights
Optimized combination
Activated immune function
Clear-cut mechanism
Efficient delivery
Long half-life
High stability
Less toxicity
Good tolerability
Low immunogenicity
Technical Superiority
Independently developed, functional domain-based molecular design and sequence optimization platform;
Short R&D cycle, easy manufacturing process, and normalizable;
Improved pharmacokinetic profile, and enhanced drug tolerability and activity.
Clinical Value
Tumor immunoregulatory factors destroy tumors mainly by activating the body's immune system. NeoCura IM can be used alone, or in combination with different immunotherapies (including various kinds of immune checkpoint inhibitors, tumor vaccines, and immune cell therapy, etc.) to exert synergistically enhanced immune effects, through which a 1+1>2 efficacy can be achieved to improve the overall response rate of tumor immunotherapy.